Lisly Chéry1, Leonardo D Borregales1, Bryan Fellman2, Diana L Urbauer2, Naveen Garg3, Nathan Parker4, Matthew H G Katz4, Christopher G Wood1, Jose A Karam5. 1. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 5. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: JAKaram@mdanderson.org.
Abstract
OBJECTIVE: To examine the effect that neoadjuvant axitinib for the treatment of localized renal cell carcinoma has on body compartment composition. MATERIALS AND METHODS: The study was based on a single-institution, single-arm clinical trial that enrolled 24 patients with locally advanced non-metastatic biopsy-proven clear cell renal cell carcinoma. Patients received axitinib orally for up to 12 weeks. Computed tomography scans were completed before the start of treatment, after 7 weeks of treatment and at the completion of 12 weeks of treatment. Patients underwent nephrectomy after axitinib treatment. The primary outcome of the current study was change in body compartment composition. Secondary outcomes included development of new-onset sarcopenia and changes in body weight. RESULTS: A total of 23 patients had a complete set of imaging for evaluation, of which 19 (82.6%) lost weight. Median weight loss was 4.5 kg (P <.001). Seven patients (30.4%) had sarcopenia before treatment, with an additional 5 (21.7%) developing sarcopenia during treatment. Median decrease in skeletal muscle was 2.9 cm2/m2 (P <.001), visceral adipose tissue was 4.9 cm2/m2 (P = .132), and subcutaneous adipose tissue was 1.0 cm2/m2 (P = .043). Ten of the 16 patients (62.5%) without baseline sarcopenia achieved a partial response, whereas only 1 of the 7 patients (14.3%) with baseline pretreatment sarcopenia achieved a partial response (P = .069). CONCLUSION:Neoadjuvant axitinib resulted in a decrease in skeletal muscle and subcutaneous adipose tissue, as well as weight loss. Patients with baseline sarcopenia tended to have a lower response rate to neoadjuvant axitinib.
RCT Entities:
OBJECTIVE: To examine the effect that neoadjuvant axitinib for the treatment of localized renal cell carcinoma has on body compartment composition. MATERIALS AND METHODS: The study was based on a single-institution, single-arm clinical trial that enrolled 24 patients with locally advanced non-metastatic biopsy-proven clear cell renal cell carcinoma. Patients received axitinib orally for up to 12 weeks. Computed tomography scans were completed before the start of treatment, after 7 weeks of treatment and at the completion of 12 weeks of treatment. Patients underwent nephrectomy after axitinib treatment. The primary outcome of the current study was change in body compartment composition. Secondary outcomes included development of new-onset sarcopenia and changes in body weight. RESULTS: A total of 23 patients had a complete set of imaging for evaluation, of which 19 (82.6%) lost weight. Median weight loss was 4.5 kg (P <.001). Seven patients (30.4%) had sarcopenia before treatment, with an additional 5 (21.7%) developing sarcopenia during treatment. Median decrease in skeletal muscle was 2.9 cm2/m2 (P <.001), visceral adipose tissue was 4.9 cm2/m2 (P = .132), and subcutaneous adipose tissue was 1.0 cm2/m2 (P = .043). Ten of the 16 patients (62.5%) without baseline sarcopenia achieved a partial response, whereas only 1 of the 7 patients (14.3%) with baseline pretreatment sarcopenia achieved a partial response (P = .069). CONCLUSION: Neoadjuvant axitinib resulted in a decrease in skeletal muscle and subcutaneous adipose tissue, as well as weight loss. Patients with baseline sarcopenia tended to have a lower response rate to neoadjuvant axitinib.
Authors: Mark J Ratain; Tim Eisen; Walter M Stadler; Keith T Flaherty; Stan B Kaye; Gary L Rosner; Martin Gore; Apurva A Desai; Amita Patnaik; Henry Q Xiong; Eric Rowinsky; James L Abbruzzese; Chenghua Xia; Ronit Simantov; Brian Schwartz; Peter J O'Dwyer Journal: J Clin Oncol Date: 2006-04-24 Impact factor: 44.544
Authors: Samantha J Cushen; Derek G Power; Min Y Teo; Peter MacEneaney; Michael M Maher; Ray McDermott; Kathleen O'Sullivan; Aoife M Ryan Journal: Am J Clin Oncol Date: 2017-02 Impact factor: 2.339
Authors: David Cella; Susan Yount; Hongyan Du; Rahul Dhanda; Kathleen Gondek; Katie Langefeld; Jacquelyn George; William P Bro; Celeste Kelly; Ronald Bukowski Journal: J Support Oncol Date: 2006-04
Authors: Pranav Sharma; Kamran Zargar-Shoshtari; Jamie T Caracciolo; Mayer Fishman; Michael A Poch; Julio Pow-Sang; Wade J Sexton; Philippe E Spiess Journal: Urol Oncol Date: 2015-06-18 Impact factor: 3.498
Authors: Sami Antoun; Laura Birdsell; Michael B Sawyer; Peter Venner; Bernard Escudier; Vickie E Baracos Journal: J Clin Oncol Date: 2010-01-19 Impact factor: 44.544
Authors: Luciana Audi de Castroneves; Marcelo Vailati Negrão; Ricardo Miguel Costa de Freitas; Carla Papadia; José Viana Lima; Julia T Fukushima; Eduardo Furquim Simão; Marco Aurélio Vamondes Kulcsar; Marcos Roberto Tavares; Alexander Augusto de Lima Jorge; Gilberto de Castro; Paulo Marcelo Hoff; Ana Oliveira Hoff Journal: Thyroid Date: 2016-02-09 Impact factor: 6.568
Authors: O Huillard; O Mir; M Peyromaure; C Tlemsani; J Giroux; P Boudou-Rouquette; S Ropert; N Barry Delongchamps; M Zerbib; F Goldwasser Journal: Br J Cancer Date: 2013-03-05 Impact factor: 7.640
Authors: Daniel D Shapiro; Melinda Soeung; Luigi Perelli; Eleonora Dondossola; Devaki Shilpa Surasi; Durga N Tripathi; Jean-Philippe Bertocchio; Federica Carbone; Michael W Starbuck; Michael L Van Alstine; Priya Rao; Matthew H G Katz; Nathan H Parker; Amishi Y Shah; Alessandro Carugo; Timothy P Heffernan; Keri L Schadler; Christopher Logothetis; Cheryl L Walker; Christopher G Wood; Jose A Karam; Giulio F Draetta; Nizar M Tannir; Giannicola Genovese; Pavlos Msaouel Journal: Cancers (Basel) Date: 2021-11-30 Impact factor: 6.639